Lucrative Conference: Benda Recognizes $1.3 Million For Gendicine Order
This article was originally published in PharmAsia News
Executive Summary
SHANGAHI - Benda has recognized $1.3 million in revenues from an order worth $3.8 million placed at a recent conference for its cancer gene therapy Gendicine, the company announced Dec 5
You may also be interested in...
Chinese Pharma Benda Reports 66 Percent Increase In Revenue For 2007
SHANGHAI - Benda Pharmaceutical announced a jump in profits for the fourth quarter and fiscal year ended December 31, 2007, mainly due to SiBiono's gross profits of $5.27 million, which Benda acquired in April 2007
Chinese Pharma Benda Reports 66 Percent Increase In Revenue For 2007
SHANGHAI - Benda Pharmaceutical announced a jump in profits for the fourth quarter and fiscal year ended December 31, 2007, mainly due to SiBiono's gross profits of $5.27 million, which Benda acquired in April 2007
Benda’s Jiangling Plant Gets Production Approval
SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22